Browsing Tag
LEO Pharma
6 posts
Why Leo Pharma’s completed Spevigo deal with Boehringer could reshape rare skin disease care
Leo Pharma completes its acquisition of Spevigo® from Boehringer Ingelheim. Learn how this rare disease drug strengthens its dermatology growth strategy.
LEO Pharma showcases promising results from DELTA 3 trial at AAD Congress
In a significant development within the field of medical dermatology, LEO Pharma A/S, a global leader renowned for…
EMA validates LEO Pharma’s application for delgocitinib cream in chronic hand eczema
LEO Pharma A/S said that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for…
Glenmark Pharmaceuticals gets FDA approval for generic Protopic Ointment
Glenmark Pharmaceuticals Ltd., a global leader in pharmaceutical research, has secured the final nod from the U.S. Food…
Can Glenmark Pharmaceuticals’ FDA approval for Enstilar Foam generic boost its U.S. dermatology footprint?
Glenmark Pharmaceuticals secures FDA approval for its generic version of Enstilar Foam, aiming to expand its U.S. dermatology market presence.
LEO Pharma secures global rights to JW1601 in $402m deal with JW Pharmaceutical
LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601…